Contact Us
Hit enter to search or ESC to close

News

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones
Alterity Therapeutics
– Preliminary Data from ATH434-202 Study Expected in 1H 2024 – – ATH434-201 Study to Complete in November 2024 – Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued a letter to shareholders. Dear Shareholders: As we begin a new ...

Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434
Alterity Therapeutics
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 16 November 2023:  Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced promising new data related to ATH434 was presented at the Society for Neuroscience that took place November 11-15, 2023, in Washington, ...

Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive Refund
Alterity Therapeutics
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 15 August 2023. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it has received a A$4.74 million cash refund from the Australian Taxation Office under the Australian Government’s Research and ...

Appendix 4C – Q4 FY23 Quarterly Cash Flow Report
Alterity Therapeutics
Highlights: MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 31 July 2023. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 30 June 2023 (Q4 ...

Alterity Therapeutics to Present in MST Access Rare Diseases, Rich Returns Forum on 22 June 2023
Alterity Therapeutics
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity will present a corporate overview and participate in a Q&A discussion at the MST Access Rare Diseases, Rich Returns Forum on Thursday, ...

Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy
Alterity Therapeutics
– ATH434 is a Disease Modifying Drug Candidate Targeting Alpha-Synuclein and Iron in Parkinsonian Disorders – – Topline Data Expected in Early 2025 – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 4 December 2024:  Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative ...

Chairman’s Address 2024 Annual General Meeting
Alterity Therapeutics
Good morning, everyone, and thank you for joining us today here in Melbourne.  It is my pleasure to share with you my Chairman’s address for Alterity Therapeutics Fiscal Year 2024 Annual General Meeting. This has been a year of significant progress and achievement for Alterity, marked by important milestones in our mission to develop disease-modifying ...

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium
Alterity Therapeutics
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 12 November 2024:  Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the presentation of data from Alterity’s Biomarkers of progression in Multiple System Atrophy (bioMUSE) natural history study at the 35th International ...

Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434
Alterity Therapeutics
– Peer-Reviewed Publication Describes How ATH434 Uniquely Targets Excess Iron – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 6 November 2024:  Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the peer-reviewed journal, Metallomics has published data on the ...

Appendix 4C – Q1 FY25 Quarterly Cash Flow Report
Alterity Therapeutics
Highlights MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 31 October 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today released its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 30 September 2024 (Q1 ...

Alterity to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024
Alterity Therapeutics
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 14 October 2024:  Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity will participate in a fireside chat at the 2024 Maxim Healthcare Virtual ...

Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting
Alterity Therapeutics
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 11 October 2024:  Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced promising new data related to ATH434 were presented at the Society for Neuroscience 2024 in Chicago, USA. The poster entitled, “Potent ...

Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®
Alterity Therapeutics
– ATH434 shows promise as a disease-modifying therapy for MSA – – ATH434-202 Phase 2 interim data demonstrate stabilization of clinical symptoms and biomarkers in clinical responders – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 2 October 2024:  Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease ...

Receive news from Alterity Therapeutics

Subscription Form